Therapeutic effects of dl-3-n-butylphthalide in a transgenic mouse model of amyotrophic lateral sclerosis

Chinese Medical Journal

Volumn 125, Issue 10, 2012, Pages 1760-1766

  Feng, Xin Hong ^a   Yuan, Wei ^b   Peng, Ying ^c   Liu, Ming Sheng ^d   Cui, Li Ying ^d  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Amyotrophic lateral sclerosis; Dl 3 n butylphthalide; SOD1 G93A mice

Indexed keywords

3 BUTYLPHTHALIDE; CD11B ANTIGEN; 3-N-BUTYLPHTHALIDE; BENZOFURAN DERIVATIVE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; ELECTROMYOGRAPHY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; MOTONEURON; MOTOR ACTIVITY; MOTOR PERFORMANCE; MOTOR UNIT POTENTIAL; MOUSE; NONHUMAN; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; FEMALE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BENZOFURANS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC;

EID: 84866667912     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.10.014     Document Type: Article

References (25)

1. Bendotti C, Carrì MT. Lessons from models of SOD1-linked familial ALS. Trends Mol Med 2004; 10: 393-400.
2. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
3. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
4. Dong GX, Feng YP. Effects of NBP on ATPase and anti-oxidant enzymes activities and lipid peroxidation in transient focal cerebral ischemic rats. Acta Acad Med Sin (Chin) 2002; 24: 93-97.
5. Li L, Zhang B, Tao Y, Wang Y, Wei H, Zhao J, et al. DL-3-n-butylphthalide protects endothelial cells against oxidative/nitrosative stress, mitochondrial damage and subsequent cell death after oxygen glucose deprivation in vitro. Brain Res 2009; 1290: 91-101.
6. Huang JZ, Chen YZ, Su M, Zheng HF, Yang YP, Chen J, et al. Dl-3-n-Butylphthalide prevents oxidative damage and reduces mitochondrial dysfunction in an MPP(+)-induced cellular model of Parkinson's disease. Neurosci Lett 2010; 475: 89-94.
7. Chang Q, Wang XL. Effects of chiral 3-n-butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol Sin 2003; 24: 796-804.
8. Zhang T, Jia W, Sun X. 3-n-Butylphthalide (NBP) reduces apoptosis and enhances vascular endothelial growth factor (VEGF) up-regulation in diabetic rats. Neurol Res 2010; 32: 390-396.
9. Li J, Li Y, Ogle M, Zhou X, Song M, Yu SP, et al. DL-3-n-Butylphthalide prevents neuronal cell death after focal cerebral ischemia in mice via the JNK pathway. Brain Res 2010; 1359: 216-226.
10. Xu HL, Feng YP. Effects of 3-n-butylphthalide on production of vasoactive substances by cerebral and aortic endothelial cells. Acta Pharmacol Sin 1999; 20: 929-933.
11. Peng Y, Xing C, Lemere CA, Chen G, Wang L, Feng YP, et al. L-3-n-butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells. Neurosci Lett 2008; 434: 224-229.
12. 1 peptide in rats. Eur J Pharmacol 2009; 621: 38-45.
13. Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, et al. L-3-n-Butylphthalide improves cognitive impairment and reduces amyloid-P in a transgenicmodel of Alzheimer's disease. J Neurosci 2010; 30: 8180-8189.
14. Gurney ME, Cutting FB, Zhai P, Andrus PK, Hall ED. Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu,Zn superoxide dismutase. Pathol Biol (Paris) 1996; 44: 51-56.
15. Karl T, Pabst R, Von Hörsten S. Behavioral phenotyping of mice in pharmacologicaI and toxicological research. Exp Toxicol Pathol 2003; 55: 69-83.
16. Weydt P, Hong SY, Kliot M, Moller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 2003; 14: 1051-1054.
17. Shefiner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D; Northeast ALS Consortium. Revised statistical motor unit number estimation in the Celecoxib/ALS trial. Muscle Nerve 2007; 35: 228-234.
18. Mohajeri MH, Figlewicz DA, Bohn MC. Selective loss of alpha motoneurons innervating the medial gastrocnemius muscle in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 1998; 150: 329-336.
19. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23: 249-256.
20. Sargsyan SA, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 2005; 51: 241-253.
21. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312: 1389-1392.
22. Sartucci F, Maritato P, Moscato G, Orlandi G, Calabrese R, Domenici GL, et al. Motor unit number estimation (mune) as a quantitative measure of disease progression and motor unit reorganization in amyotrophic lateral sclerosis. Int J Neurosci 2007; 117: 1229-1236.
23. Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, et al. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J Neuroinflammation 2006; 3: 2.
24. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 459-470.
25. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23: 249-256.